Devyser Diagnostics AB publishes quarterly report for the period April to June 2023
“The second quarter of the year saw an improvement in EBIT compared with recent quarters, continued high gross margins, strong growth and an exclusive collaboration and distribution agreement with US-based Thermo Fisher Scientific. Two new oncology products and one new transplant product were launched during the quarter. Our CLIA-certified laboratory in Atlanta was inaugurated and the first patient test was carried out in this laboratory.” Fredrik Alpsten, CEO, Devyser The quarter from April to June 2023 · Net sales amounted to SEK 37.7 million (30.9), corresponding to a 22.3%